Recent Company News

• 07:00 PM ET Apr 29, 2025
  

  Opthea reports Q3 net cash used in operating activities ($32.4M) - Appendix 4C (A$0.60, 0.00)

• 07:27 PM ET Apr 09, 2025
  

  Opthea to reduce workforce by ~65% following negative trial results (A$0.60, 0.00)

• 04:37 PM ET Apr 01, 2025
  

  Opthea downgraded to sell from buy at Bell Potter (A$0.60, 0.00)

• 09:54 PM ET Mar 30, 2025
  

  Opthea shares to remain suspended (A$0.60, 0.00)

• 09:52 PM ET Mar 30, 2025
  

  Opthea reports ShORe Phase 3 trial fails to meet primary endpoint; Opthea and DFA Investors agree to terminate both COAST and ShORe trials (A$0.60, 0.00)

• 04:55 PM ET Mar 24, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:48 AM ET Mar 25, 2025
  

  Opthea downgraded to neutral from buy at HC Wainwright ($3.41, 0.00)

• 08:31 AM ET Mar 25, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:41 PM ET Mar 24, 2025
  

  Opthea downgraded to underperform from buy at Jefferies ($3.41, 0.00)